Skip to main content
SpringerLink
Log in

A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth

  • Published:
Angiogenesis Aims and scope Submit manuscript

Abstract

We put forward an algorithm describing the three principal interconnected sub-processes that influence tumor and vasculature dynamics: (i) tumor cell proliferation (ii) angiogenesis, that is, the formation and regression of immature vessels (IV), and (iii) maturation, i.e., the formation and destabilization of mature vessels (MV). This algorithm takes account of the crucial quantitative interactions of these sub-processes, occurring across the molecular, cellular and organ levels. Implementing this complex algorithm in a computer model, one can evaluate the correlations between various factors influencing angiogenesis and their influence on tumor progression at any given moment. Moreover, the computer simulations enable analysis of the versatile effects of drugs on the growth and decay of both the tumor and the immature and mature blood vessels, as well as on the induction of an array of relevant growth factors such as angiopoietin-1 (Ang1), angiopoietin-2 (Ang2), vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Simulation results suggest that vessel maturation and destabilization of MV drive the otherwise non-linearly growing system into a very dynamic region, having irregular, scale-invariant, fluctuations, around certain asymptotic values of all the involved quantities. Destabilization itself adequately explains the experimentally observed eventual decrease of tumor growth, with no need to implicate additional assumptions, such as a new tumor growth inhibitory, or anti-angiogenic, factors. Our results further suggest that mono-therapy alone can slow tumor growth, but is not capable of eliminating it altogether. In contrast, the combined treatment of anti-angiogenic and anti-maturation drugs causes prolonged suppression of tumor growth and a significant linear decrease in average tumor size. Laboratory experiments are warranted for validating our predictions and for providing in vivo evaluated parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1(1): 27–31.

    Google Scholar 

  2. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182–6.

    Google Scholar 

  3. O'Reilly MS et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315–28.

    Google Scholar 

  4. O'Reilly MS et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–85.

    Google Scholar 

  5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249–57.

    Google Scholar 

  6. Yangopoulos GD, Davis S, Gale NW et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242–8.

    Google Scholar 

  7. Kerbel RS. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000; 21: 505–15.

    Google Scholar 

  8. Danielsen T, Rofstad EK. The constitutive level of vascular endothelial growth factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the angiogenesis of human melanoma xenografts. Br J Cancer 2000; 82(9): 1528–34.

    Google Scholar 

  9. Dor Y, Porat R, Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. AJP-Cell Physiol 2001; 280(6): C1367–74.

    Google Scholar 

  10. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995; 270(34): 19761–6.

    Google Scholar 

  11. Lin P et al. Anti-angiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie-2. Proc Natl Acad Sci 1998; 95: 8829–34.

    Google Scholar 

  12. Diaz Flores L et al. Microvascular pericytes: A review of their morphological and functional characteristics. Histol Histopathol 1991; 6: 269–86.

    Google Scholar 

  13. Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992; 114: 521–32.

    Google Scholar 

  14. Shweiki D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843–5.

    Google Scholar 

  15. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851–8.

    Google Scholar 

  16. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18–32.

    Google Scholar 

  17. Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439–42.

    Google Scholar 

  18. Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435–9.

    Google Scholar 

  19. Barleon B, Sozzani S, Zhou D et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336–43.

    Google Scholar 

  20. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB 1999; 13: 9–22.

    Google Scholar 

  21. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastomalike vessels by VEGF withdrawal. Proc Natl Acad Sci 1997; 94: 8761–6.

    Google Scholar 

  22. Jain RK, Safabakhsh N, Sckell A et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci 1998; 95(18): 10820–25.

    Google Scholar 

  23. Holash SJ, Wiegandand GD, Yancopoulos GD. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18: 5356–62.

    Google Scholar 

  24. Gilead A, Neeman M. Dynamic remodeling of the vascular bed precedes tumor growth: MLS ovarian carcinoma spheroids implanted in nude mice. Neoplasia 1999; 1: 226–30.

    Google Scholar 

  25. Benjamin LE et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103(2): 159–65.

    Google Scholar 

  26. Benjamin LE et al. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125(9): 1591–8.

    Google Scholar 

  27. Currie MJ et al. Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling. Clin Cancer Res 2001; 7: 918–27.

    Google Scholar 

  28. Koga K et al. Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 2001; 61: 6248–54.

    Google Scholar 

  29. Davis S, Aldrich TH, Jones PF et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161–9.

    Google Scholar 

  30. Suri C, Jones PE, Patan S et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171–80.

    Google Scholar 

  31. Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55–60.

    Google Scholar 

  32. Audero E et al. Expression of Angiopoietin-1 in human glioblastoma regulates tumor-induced angiogenesis. Arterioscl Thromb Vasc Biol 2001; 21: 536–41.

    Google Scholar 

  33. Stratmann A. Cell type-specific expression of Angiopoietin-1 and Angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998; 153: 1459–66.

    Google Scholar 

  34. Kakolyris S et al. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component. Br J Cancer LH39 2000; 82: 844–51.

    Google Scholar 

  35. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7: 987–9.

    Google Scholar 

  36. Hahnfeldt P et al. Tumor development under angiogenic signaling: A dynamic theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999; 59: 4770–5.

    Google Scholar 

  37. Bellomo N, Preziosi L. Modelling and mathematical problems related to tumor evolution and its interaction with the immune system. Math Comp Modell 2000; 32: 413–52.

    Google Scholar 

  38. De Angelis E, Preziosi L. Advection-diffusion models for solid tumour evolution in vivo and related free boundary problem. Math Models Meth Appl 2000; 10: 379–408.

    Google Scholar 

  39. Folkman J, D'Amore PA. Blood vessel formation: What is its molecular basis? Cell 1996; 87: 1153–5.

    Google Scholar 

  40. Darland DC, D'Amore PA. Blood vessel maturation: Vascular development comes of age. J Clin Invest 1999; 103(2): 157–8.

    Google Scholar 

  41. Ahmad SA et al. Differential expression of Angiopoietin-1 and Angiopoietin-2 in colon carcinoma. Cancer 2001; 92: 1138–43.

    Google Scholar 

  42. Arakelyan L et al. Multi-scale analysis of angiogenic dynamics and therapy. In Luigi Preziosi (ed): Cancer Modelling and Simulation, UK: CRC Press (in press).

  43. Segel LA. Developmental pattern formation and stability theory. In Modeling Dynamic Phenomena in Molecular and Cellular Biology, Chapter 7. Cambridge: Cambridge University Press, 1984.

    Google Scholar 

  44. Norton LA. Gompertzian model of human breast cancer growth. Cancer Res 1988; 48: 7067–71.

    Google Scholar 

  45. Folkman J. Cancer: Looking outside the genome. Nat Rev Mol Cell Biol 2000; 1: 76–9.

    Google Scholar 

  46. Holash J et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284(5422): 1994–8.

    Google Scholar 

  47. Folberg R et al. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000 156(2): 361–81.

    Google Scholar 

  48. Murayama T. Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factorinduced neovascularization in vivo. Exp Hematol 2002; 30(8): 967–72.

    Google Scholar 

  49. Garber K. Angiogenesis inhibitors suffer new setback. Nat Biotechnol 2002; 20: 1067–8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Medical Biomathematics, Bene Ataroth, Israel

    L. Arakelyan & V. Vainstein

  2. Institute for Medical Biomathematics, 10, Ha' Teena Street, Bene Ataroth, 60991, Israel

    Z. Agur

Authors
  1. L. Arakelyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Vainstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z. Agur
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arakelyan, L., Vainstein, V. & Agur, Z. A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth. Angiogenesis 5, 203–214 (2002). https://doi.org/10.1023/A:1023841921971

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1023841921971

Search

Navigation